An observational study in Smoke Inhalation Patients, sponsored by Saint-Louis Hospital, Paris, France. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-04-04.
Sponsored by Saint-Louis Hospital, Paris, France · Observational
Among 154 studies in Acute Kidney Injury with a site in France — 31 open to participants now, 35 under way, 4 of them phase 3. Acute Kidney Injury · France.
Among the 154 studies in Acute Kidney Injury with a site in France, this one is the 14th largest by enrollment of the 76 observational ones that give a count, is one of 7 that started in 2017, is one of 76 observational ones, and was the 56th registered.
1,691 studies on the registry are indexed under Acute Kidney Injury; 394 are open to participants now.
Browse Acute Kidney Injury studies →31 of the 154 studies in Acute Kidney Injury with a site in France are open now. Recruiting first, the newest first:
Centre Hospitalier Universitaire de Nīmes · Sites in France
Ages 18+
Uppsala University · Sites in France, Australia, Brazil and 7 more countries
Ages 0–16
AstraZeneca · Sites in France, United States, Argentina and 11 more countries
Ages 18–80
Hospices Civils de Lyon · Sites in France
Ages 18+
University Hospital, Bordeaux · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 230 Acute Kidney Injury studies recruiting now, 161 (70%) set no upper age limit and 36 (16%) stop at 75 or younger; 22 take children under 18; 25 take healthy volunteers.
This study: 18 Years and older · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
154 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 11 · Phase 3 22 · Phase 4 5
First in 2004; this study’s year is marked. 7 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 739 is above the median of 160 across 814 observational studies indexed under Acute Kidney Injury.
Median enrollment 150 across the 78 interventional studies, 190 across the 76 observational. Of the 105 that completed or were terminated, 8 (8%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 154 have an industry lead sponsor. The 10 most frequent:
Saint-Louis Hospital, Paris, France is the lead sponsor of 8 studies on the registry; 1 is open to participants now.
Saint-Louis Hospital, Paris, France has 1 study filed under Acute Kidney Injury — fewer than ten, so there is no comparison to draw.
11 of the studies in Acute Kidney Injury with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03329313University Hospital, MontpellierEffects of Variation of Sodium Dialysate in ICU | 2026-12-19 |
| NCT06823115Indiana UniversityAssessment of Worldwide Acute Kidney Injury Epidemiology in Neonates 2.0 | 2027-01 |
| NCT04264065Assistance Publique - Hôpitaux de ParisAlbumin and Prognosis of Severely Patients Burns | 2027-01-16 |
| NCT07215702AstraZenecaA Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kidney Injury. | 2027-02-11 |
| NCT07596407Assistance Publique - Hôpitaux de ParisAcute Kidney Injury : Long-term Renal and Cardiovascular Prognosis and Biomarker-based Risk Assessment | 2027-05-30 |
Add all 11 to your calendar (.ics) → With an account.
Among the 154 studies in Acute Kidney Injury with a site in France, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
In Europe, hydroxocobalamin (cyanokit) has been used for suspicion of cyanide intoxication associated with the inhalation of fire smoke (1). However, the impact of hydroxocobalamin on outcome has never been thoroughly evaluated. While hydroxocobalamin has long been presented as being side-effect free, recent data suggest that in patients with severe burns, its use was associated with the occurrence of acute renal failure by intra tubular precipitation of oxalate crystals (2, 3). The purpose of this observational study is to investigate the association between use of hydroxocobalamin and outcome after smoke inhalation.
In Europe, hydroxocobalamin (cyanokit) is the antidote recommended by expert consensus in cases of suspicion of cyanide intoxication associated with the inhalation of fire smoke (1). However, cyanokit has never been evaluated in this indication. Clinical data suggest that in patients with severe burns, its use is associated with the occurrence of acute kidney injury by intra tubular precipitation of oxalate crystals (2, 3). The purpose of this observational study is to investigate the association between use of hydroxocobalamin and outcome after smoke inhalation. The results of this study should guide future research and advice on the benefit-risk ratio of hydroxocobalamin.
Patients with smoke inhalation injury admitted in ICU
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
There is no intervention planned (observational)
in ICU mortality
mortality in ICU or at day 90
Time frame: through study completion, an average of 1 year
in ICU acute kidney injury (based on the KDIGO definition)
AKI in ICU or at day 90
Time frame: through study completion, an average of 1 year
Major Adverse Kidney Events
MAKE in ICU or at day 90
Time frame: through study completion, an average of 1 year
in ICU length of stay alive
through study completion, an average of 1 year
Time frame: through study completion, an average of 1 year
Plan to share: No
Ran from Jun 2017 to primary completion in Dec 2018, 18 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Saint-Louis Hospital, Paris, France